In this week’s EuroBiotech Report, after years of relying heavily on Neil Woodford’s checkbook, early-stage British and European biotechs could soon have another big-name investor to tap for cash: Jim Mellon–a man worth around £800 million ($1.2 billion)–is preparing to get deeper into biotech with a £100 million fund. And more.

…read more

Source: Big shot investor plans £100M EU biotech fund, Genmab up on PhII data, J&J inks U.K. RA deal


0 No comments